Spinal Muscular Atrophy Market Size Forecast: Revenue and CAGR by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Spinal Muscular Atrophy Industry In 2025?

The spinal muscular atrophy market size has seen swift expansion in recent years. It is anticipated to increase from $3.53 billion in 2024 to $4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.3%. This historical growth can be linked to several factors including increased diagnosis and early detection, the rising prevalence of rare genetic disease, advancements in healthcare infrastructure, support from government and regulatory bodies, and a growth in unmet healthcare needs.

The spinal muscular atrophy market is anticipated to experience substantial growth over the upcoming years, with projections indicating it will reach $6.53 billion by 2029, achieving a compound annual growth rate (CAGR) of 13.0%. This expansion during the forecast period is primarily driven by heightened awareness and improved diagnosis, increased access to treatments, greater healthcare investments targeting rare diseases, a supportive regulatory landscape, and rising healthcare expenditure. Notable trends emerging in this period involve progress in oral therapies, the increasing adoption of gene therapy, technological improvements in drug delivery systems, the integration of artificial intelligence into SMA treatment development, and advancements in gene editing technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

Which Drivers Are Supporting Growth Of The Spinal Muscular Atrophy Market?

The increasing occurrence of rare genetic diseases is anticipated to boost the expansion of the spinal muscular atrophy market moving forward. These conditions are disorders caused by genetic mutations, affecting a small segment of the population and often leading to severe, chronic health problems. The growing prevalence of rare genetic diseases can be attributed to advancements in diagnostic technologies, heightened awareness, and improved access to genetic testing, which results in more cases being identified and reported. Spinal muscular atrophy (SMA) is a rare genetic disorder that exemplifies both the difficulties and opportunities involved in understanding inherited diseases. It underscores the importance of advancing research into genetic conditions. For instance, in July 2023, as per a report published by the Office for National Statistics, a UK-based government department, genetic testing of SMN1 has enabled precise epidemiological studies, revealing that SMA occurs in 1 of 10,000 to 20,000 live births and that more than 95% of affected patients are homozygous for SMN1 deletion. Therefore, the rising prevalence of rare genetic diseases will stimulate the growth of the spinal muscular atrophy market.

What Are The Key Segments In The Spinal Muscular Atrophy Market?

The spinal muscular atrophymarket covered in this report is segmented –

1) By Type: Type 1 (Severe); Type 2 (Intermediate); Type 3 (Mild); Type 4 (Adult)

2) By Age: Pediatric; Adults

3) By Treatment: Drug Therapy; Gene Therapy

4) By End User: Hospital pharmacy; Online pharmacy; Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA; Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA; Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA; Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA; Late-Onset SMA

How Are Trends Influencing The Spinal Muscular Atrophy Market?

Major companies operating in the spinal muscular atrophy market are creating innovative products, such as dry syrup, to enhance medication adherence and ease of administration for pediatric and other patient groups who experience swallowing difficulties. Dry syrup is a powdered medication that requires reconstitution with water before use, frequently prescribed for children and individuals who struggle with swallowing tablets or capsules. For example, in September 2024, Chugai Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, announced that Japan’s Ministry of Health, Labour and Welfare had granted regulatory approval for an expanded indication of its drug Evrysdi (risdiplam). This approval permits its use in pre-symptomatic spinal muscular atrophy (SMA) and extends dosing to infants younger than two months old. This achievement is vital as it allows treatment to begin before symptoms emerge, potentially improving therapeutic outcomes for affected infants. The decision was supported by findings from the RAINBOWFISH study, which assessed Evrysdi’s safety and efficacy in infants diagnosed with SMA but not yet displaying symptoms. Results showed that treated infants reached developmental milestones, such as unsupported sitting and enhanced motor skills, by 12 months, emphasizing the drug’s potential to alter the disease’s progression when administered early.

Who Are The Core Companies Influencing The Spinal Muscular Atrophy Market Landscape?

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Biohaven Ltd., Catalyst Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

Which Geographies Are Emerging As Strong Markets For The Spinal Muscular Atrophy Industry?

North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Spinal Muscular Atrophy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Market 2025, By The Business Research Company

Optic Atrophy Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Spinal Surgery Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/spinal-surgery-devices-and-equipment-global-market-report

Cerebrospinal Fluid Management Csf Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cerebrospinal-fluid-management-csf-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795